Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23563123 | 0.81 | HPGD (0.46) | HPGDKMT2AARHTTPTGS1 | |
| SCHEMBL12314797 | 0.81 | PIK3CB (0.51) | HPGDALDH1A1KMT2AHTTPTGS1 | |
| SCHEMBL15034013 | 0.78 | HPGD (0.55) | HPGDALDH1A1PRMT6PIK3C3POLB | |
| SCHEMBL18948385 | 0.77 | BRD4 (0.38) | HPGDKMT2APTGS1PARP1 | |
| SCHEMBL3093140 | 0.77 | ALDH1A1 (0.47) | HPGDALDH1A1PRMT6PIK3C3POLB | |
| SCHEMBL11918321 | 0.76 | HPGD (0.42) | HPGDALDH1A1PRMT6PIK3C3POLB | |
| SCHEMBL14194063 | 0.75 | HPGD (0.65) | HPGDALDH1A1POLBMEN1KMT2A | |
| SCHEMBL19728973 | 0.74 | ALDH1A1 (0.45) | HPGDALDH1A1PRMT6PIK3C3POLB | |
| SCHEMBL18948388 | 0.74 | HPGD (0.48) | HPGDALDH1A1PRMT6PIK3C3POLB | |
| SCHEMBL4493666 | 0.74 | HPGD (1.00) | HPGDALDH1A1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-12-21 | — | — | US | disclosed |
| EP-2516417-B1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMA (US) | 2017-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | HPGD 4313/4885ALDH1A1 4653/4885PRMT6 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.